Thermo Fisher Scientific insider trading
Every open-market purchase and sale by Thermo Fisher Scientific's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Thermo Fisher Scientific’s insiders pay?
From March 4, 2010 to October 30, 2026, 26 insiders reported 4 open-market purchases and 128 sales not made under a pre-set plan in Thermo Fisher Scientific. Twelve months after each purchase was reported, the shares were −3.9% against the S&P 500 on average (median −0.9%), over 4 purchases with a full year of prices; 50% beat the index. After sales, the shares moved +4.5% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 9, 2010 into $13,803 by November 2, 2026, +2.0% a year. It held shares 19% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $17,012 (+3.3% a year), and held throughout $89,141 (+14.5%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Manzi Jim P | Director | 0 | — | — | 19 | +2.5% (19) | February 7, 2023 |
| Malus Alan J | Executive Vice President | 0 | — | — | 10 | +6.3% (10) | March 14, 2016 |
| Lagarde Michel | Executive Vice President & COO | 0 | — | — | 9 | −7.8% (6) | December 5, 2025 |
| Pesicka Edward A | Senior Vice President | 0 | — | — | 8 | +8.7% (8) | March 9, 2015 |
| Harris C Martin | Director | 0 | — | — | 7 | +7.6% (7) | June 6, 2019 |
| Herrema Gregory J. | Senior Vice President | 1 | +6.9% (1) | 100% | 6 | +11.1% (6) | March 5, 2019 |
| Wilver Peter M | Exec. VP & Chief Admin Officer | 0 | — | — | 7 | +16.6% (7) | March 16, 2017 |
| Britt Lisa P. | Sr. VP and Chief HR Officer | 0 | — | — | 6 | −40.6% (1) | October 30, 2026 |
| Porter Michael E | Director | 0 | — | — | 6 | −1.4% (6) | March 12, 2012 |
| Loewald Thomas W | Senior Vice President | 0 | — | — | 5 | +5.7% (5) | February 23, 2015 |
| Ullian Elaine | Director | 0 | — | — | 5 | +14.8% (5) | May 8, 2013 |
| Casper Marc N | Chairman & CEO | 1 | +7.4% (1) | 100% | 3 | −11.3% (3) | November 4, 2020 |
| Holmes Joseph R. | VP & Chief Accounting Officer | 0 | — | — | 4 | −6.5% (3) | August 10, 2026 |
| Hoogasian Seth H | Sr. VP, Gen. Counsel & Sec. | 0 | — | — | 4 | +17.4% (4) | August 11, 2016 |
| Jacks Tyler | Director | 0 | — | — | 4 | +18.9% (4) | December 4, 2018 |
| Parrett William G | Director | 1 | −8.8% (1) | 0% | 3 | +8.6% (3) | February 27, 2018 |
| Sperling Scott M | Director | 0 | — | — | 4 | +3.9% (4) | March 7, 2016 |
| Hornstra Peter E | VP & Chief Accounting Officer | 0 | — | — | 3 | −6.6% (3) | August 19, 2020 |
| Spar Debora L | Director | 0 | — | — | 3 | −18.7% (3) | February 14, 2024 |
| Thomson Andrew J | Senior Vice President | 0 | — | — | 3 | +15.7% (3) | February 18, 2014 |
| Williamson Stephen | Sr. VP and CFO | 0 | — | — | 3 | +13.4% (3) | July 31, 2020 |
| Berger Kenneth | Senior Vice President | 0 | — | — | 2 | +4.0% (2) | September 14, 2010 |
| Manning Peter J | Director | 0 | — | — | 2 | −2.0% (2) | March 3, 2011 |
| Boxer Michael A | SVP and General Counsel | 0 | — | — | 1 | −28.9% (1) | March 11, 2025 |
| Chai Nelson | Director | 1 | −21.2% (1) | 0% | 0 | — | February 21, 2025 |
| Jafry Syed A. | Sr. Vice President | 0 | — | — | 1 | −5.6% (1) | July 29, 2020 |
When several insiders traded Thermo Fisher Scientific
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Thermo Fisher Scientific in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −1.3% against the index. After 14 selling crowds, −0.7%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| November 28, 2025 | 3 selling | −13.8% | −30.0% | not yet |
| July 31, 2024 | 3 selling | −16.6% | −12.4% | −39.7% |
| August 31, 2020 | 4 selling | +4.4% | −4.9% | −1.6% |
| February 28, 2018 | 3 selling | +0.5% | +6.6% | +21.8% |
| September 29, 2017 | 3 selling | −6.3% | +4.7% | +13.5% |
| August 31, 2016 | 3 selling | −9.7% | −5.4% | +7.3% |
| February 27, 2015 | 3 selling | −0.8% | +3.1% | +6.1% |
| August 29, 2014 | 4 selling | +4.0% | +1.9% | +4.4% |
| February 28, 2014 | 8 selling | −9.9% | −11.8% | −10.0% |
| May 31, 2013 | 5 selling | +0.2% | +2.8% | +12.4% |
| August 31, 2012 | 3 selling | +10.6% | +23.0% | +39.2% |
| May 31, 2012 | 3 selling | +5.4% | +17.2% | +49.3% |